INTRODUCTION
Variations in the epidemiology, clinical presentation, disease course, and impact on quality of life have been reported in SOC populations.1 Epidemiologic studies focused on atopic dermatitis (AD) suggest a higher prevalence among self-identified African Americans and greater health care utilization for AD among African Americans and Asian/Pacific Islanders.2 Data from the US has also identified a higher prevalence and persistence of AD in African-American children. In addition, racial/ethnic disparities in health care utilization and access to therapies have been identified in some SOC populations.2-6
Clinically, AD can present differently in some SOC populations. Evidence suggests investigators may under-score skin signs in patients with SOC in clinical trials.1 Nuanced expression of erythema and post-inflammatory pigmentary alteration may be observed in SOC patients with AD.1,7-10 Black patients may show more frequent follicular accentuation, lichenoid morphologies, and papulonodular presentations.1,7-10 Recognizing morpho-logical variations and differing clinical presentations in SOC AD patients is important for an accurate diagnosis, while early treatment to reduce inflammation and pigmentary sequela may
Clinically, AD can present differently in some SOC populations. Evidence suggests investigators may under-score skin signs in patients with SOC in clinical trials.1 Nuanced expression of erythema and post-inflammatory pigmentary alteration may be observed in SOC patients with AD.1,7-10 Black patients may show more frequent follicular accentuation, lichenoid morphologies, and papulonodular presentations.1,7-10 Recognizing morpho-logical variations and differing clinical presentations in SOC AD patients is important for an accurate diagnosis, while early treatment to reduce inflammation and pigmentary sequela may
